High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
J Haroche, F Charlotte, L Arnaud… - Blood, The Journal …, 2012 - ashpublications.org
J Haroche, F Charlotte, L Arnaud, A Von Deimling, Z Hélias-Rodzewicz, B Hervier…
Blood, The Journal of the American Society of Hematology, 2012•ashpublications.orgHistiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis.
BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We
investigated the frequency of BRAF mutations in several types of histiocytoses. Histology
from 127 patients with histiocytoses were reviewed. Detection of BRAFV600 mutations was
performed by pyrosequencing of DNA extracted from paraffin embedded samples.
Diagnoses of Erdheim-Chester disease (ECD), LCH, Rosai-Dorfman disease, juvenile …
BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We
investigated the frequency of BRAF mutations in several types of histiocytoses. Histology
from 127 patients with histiocytoses were reviewed. Detection of BRAFV600 mutations was
performed by pyrosequencing of DNA extracted from paraffin embedded samples.
Diagnoses of Erdheim-Chester disease (ECD), LCH, Rosai-Dorfman disease, juvenile …
Abstract
Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis. BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We investigated the frequency of BRAF mutations in several types of histiocytoses. Histology from 127 patients with histiocytoses were reviewed. Detection of BRAFV600 mutations was performed by pyrosequencing of DNA extracted from paraffin embedded samples. Diagnoses of Erdheim-Chester disease (ECD), LCH, Rosai-Dorfman disease, juvenile xanthogranuloma, histiocytic sarcoma, xanthoma disseminatum, interdigitating dendritic cell sarcoma, and necrobiotic xanthogranuloma were performed in 46, 39, 23, 12, 3, 2, 1, and 1 patients, respectively. BRAF status was obtained in 93 cases. BRAFV600E mutations were detected in 13 of 24 (54%) ECD, 11 of 29 (38%) LCH, and none of the other histiocytoses. Four patients with ECD died of disease. The high frequency of BRAFV600E in LCH and ECD suggests a common origin of these diseases. Treatment with vemurafenib should be investigated in patients with malignant BRAFV600E histiocytosis.
ashpublications.org